Format

Send to

Choose Destination
Med Res Rev. 2020 Feb 11. doi: 10.1002/med.21661. [Epub ahead of print]

The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.

Author information

1
Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts.
2
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
3
Merck & Co, Inc, Kenilworth, New Jersey.
4
Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by progressive loss of muscle function. It is the most common adult-onset form of motor neuron disease, affecting about 16 000 people in the United States alone. The average survival is about 3 years. Only two interventional drugs, the antiglutamatergic small-molecule riluzole and the more recent antioxidant edaravone, have been approved for the treatment of ALS to date. Therapeutic strategies under investigation in clinical trials cover a range of different modalities and targets, and more than 70 different drugs have been tested in the clinic to date. Here, we summarize and classify interventional therapeutic strategies based on their molecular targets and phenotypic effects. We also discuss possible reasons for the failure of clinical trials in ALS and highlight emerging preclinical strategies that could provide a breakthrough in the battle against this relentless disease.

KEYWORDS:

ALS preclinical strategies; amyotrophic lateral sclerosis; clinical trials; edaravone; riluzole

PMID:
32043626
DOI:
10.1002/med.21661

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center